The use of benzodiazepine receptor agonists (BZRAs) was linked to a reduced incidence of irAEs in patients with NSCLC receiving anti‐PD‐1/PD‐L1 monotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.